{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=55&state=Florida", "query": { "state": "Florida", "city": "Orlando", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 6860, "total_pages": 686, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=56&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=54&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T12:52:47.675Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01146652", "title": "Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2023, "start_date": "2010-06-21", "completion_date": "2020-12-31", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 75, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 66 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01146652" }, { "nct_id": "NCT04020016", "title": "Study of Nalbuphine ER in Participants With Hepatic Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "Nalbuphine ER", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trevi Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2019-06-12", "completion_date": "2020-02-05", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020016" }, { "nct_id": "NCT01197755", "title": "Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "fostamatinib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 323, "start_date": "2010-09", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-04-07", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 67, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01197755" }, { "nct_id": "NCT01194414", "title": "A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "tocilizumab SC", "type": "DRUG" }, { "name": "tocilizumab IV", "type": "DRUG" }, { "name": "placebo to tocilizumab SC", "type": "DRUG" }, { "name": "placebo to tocilizumab IV", "type": "DRUG" }, { "name": "Disease-modifying antirheumatic drugs (DMARDs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1262, "start_date": "2010-09", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2016-06-20", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 54, "location_summary": "Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 48 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01194414" }, { "nct_id": "NCT06544733", "title": "Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "Lepetegravir", "type": "DRUG" }, { "name": "Lenacapavir pacfosacil", "type": "DRUG" }, { "name": "Placebo to Match BVY", "type": "DRUG" }, { "name": "Bictegravir/emtricitabine/tenofovir alafenamide", "type": "DRUG" }, { "name": "Lepetegravir/Lenacapavir pacfosacil FDC", "type": "DRUG" }, { "name": "Placebo to Match GS1720/GS-4182 FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 675, "start_date": "2024-08-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06544733" }, { "nct_id": "NCT01778049", "title": "Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "BI 10773 Placebo", "type": "DRUG" }, { "name": "BI 10773 / BI 1356", "type": "DRUG" }, { "name": "BI 10773 / BI 1356 Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 708, "start_date": "2013-01", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-04-04", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 24, "location_summary": "Chino, California • Huntington Beach, California • San Diego, California + 20 more", "locations": [ { "city": "Chino", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sylmar", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01778049" }, { "nct_id": "NCT02050815", "title": "MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "MEK162", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 27, "start_date": "2014-03", "completion_date": "2016-08-26", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 5, "location_summary": "Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more", "locations": [ { "city": "Lakewood", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02050815" }, { "nct_id": "NCT00068952", "title": "Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Edotecarin", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Carmustine (BCNU)", "type": "DRUG" }, { "name": "Lomustine (CCNU)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2003-08", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2008-04-01", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068952" }, { "nct_id": "NCT00320385", "title": "Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 296, "start_date": "2005-11", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2016-02-26", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 87, "location_summary": "Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Highland", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320385" }, { "nct_id": "NCT00972335", "title": "Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Intracranial Meningioma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2010-01", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2021-11-10", "last_synced_at": "2026-11-06T12:52:47.675Z", "location_count": 7, "location_summary": "Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972335" } ] }